HC Wainwright & Co. Maintains Buy on WAVE Life Sciences, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on WAVE Life Sciences (NASDAQ:WVE) and raises the price target from $8 to $15.

March 07, 2024 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on WAVE Life Sciences and increases the price target from $8 to $15.
The increase in the price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish outlook on the stock, suggesting a potential upside. This is based on the analyst's research and understanding of the company's prospects, which can influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100